Arm CZ of ANHL12P1 demonstrated that the addition of CZ to standard treatment prevented relapses during therapy for children with ALCL, MDD predicted EFS, and the addition of CZ resulted in unexpected thromboembolic events. Overall survival and EFS rates are consistent with the highest reported outcomes for children with ALCL.
No takes yet. Share an insight, caveat, or question.
Lowe et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: